2025-2031 Global Influenza Vaccination Industry Research & Trends Analysis Report- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > 2025-2031 Global Influenza Vaccination Industry Research & Trends Analysis Report

2025-2031 Global Influenza Vaccination Industry Research & Trends Analysis Report

Publication Date: 2025-12-12
Report Id: 2862875
Industry: Pharma & Healthcare
Report Page: 130
Chart: 133

PDF Download

Publication Date: 2025-12-12
Report Id: 2862875
Industry: Pharma & Healthcare
Report Page: 130
Chart: 133

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Product Overview and Scope of Influenza Vaccination
1.2 Global Influenza Vaccination Market Size and Forecast
1.3 China Influenza Vaccination Market Size and Forecast
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Influenza Vaccination Share in Global Market, 2020-2031
1.4.2 Influenza Vaccination Market Size: China VS Global, 2020-2031
1.5 Influenza Vaccination Market Dynamics
1.5.1 Influenza Vaccination Market Drivers
1.5.2 Influenza Vaccination Market Restraints
1.5.3 Influenza Vaccination Industry Trends
1.5.4 Influenza Vaccination Industry Policy

2 Competitive Landscape by Company
2.1 Global Influenza Vaccination Revenue by Company, 2020-2025
2.2 Global Influenza Vaccination Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Influenza Vaccination Concentration Ratio
2.4 Global Influenza Vaccination Mergers & Acquisitions, Expansion Plans
2.5 Global Influenza Vaccination Manufacturers Product Type
2.6 Global Geographic Distribution of Influenza Vaccination Companies

3 China Competitive Situation by Company
3.1 China Influenza Vaccination Revenue by Company, 2020-2025
3.2 China Influenza Vaccination Influenza Vaccination Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.3 China Influenza Vaccination Market, Revenue Percentage of Local Players VS Foreign Players (2020-2031)

4 Industry Chain Analysis
4.1 Influenza Vaccination Industry Chain
4.2 Influenza Vaccination Upstream Analysis
4.3 Influenza Vaccination Midstream Analysis
4.4 Influenza Vaccination Downstream Analysis

5 Sights by Type
5.1 Influenza Vaccination Classification by Type
5.1.1 Trivalent Influenza Vaccine
5.1.2 Quadrivalent Influenza Vaccine
5.2 by Type, Global Influenza Vaccination Market Size & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Influenza Vaccination Market Size, 2020-2031

6 Sights by Technology
6.1 Influenza Vaccination Classification by Technology
6.1.1 Chicken Embryo Technology
6.1.2 Cell Culture Technology
6.1.3 Recombinant Technology
6.1.4 Adjuvant Vaccines
6.2 by Technology, Global Influenza Vaccination Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Technology, Global Influenza Vaccination Market Size, 2020-2031

7 Sights by Administration
7.1 Influenza Vaccination Classification by Administration
7.1.1 Injectable
7.1.2 Nasal Spray
7.2 by Administration, Global Influenza Vaccination Market Size & CAGR, 2020 VS 2024 VS 2031
7.3 by Administration, Global Influenza Vaccination Market Size, 2020-2031

8 Sights by Application
8.1 Influenza Vaccination Segment by Application
8.1.1 6 Months to 3 Years
8.1.2 > 3 Years
8.2 by Application, Global Influenza Vaccination Market Size & CAGR, 2020 VS 2024 VS 2031
8.3 by Application, Global Influenza Vaccination Market Size, 2020-2031

9 Sights by Region
9.1 By Region, Global Influenza Vaccination Market Size, 2020 VS 2024 VS 2031
9.2 By Region, Global Influenza Vaccination Market Size, 2020-2031
9.3 North America
9.3.1 North America Influenza Vaccination Market Size & Forecasts, 2020-2031
9.3.2 By Country, North America Influenza Vaccination Market Size Market Share
9.4 Europe
9.4.1 Europe Influenza Vaccination Market Size & Forecasts, 2020-2031
9.4.2 By Country, Europe Influenza Vaccination Market Size Market Share
9.5 Asia Pacific
9.5.1 Asia Pacific Influenza Vaccination Market Size & Forecasts, 2020-2031
9.5.2 By Country/Region, Asia Pacific Influenza Vaccination Market Size Market Share
9.6 South America
9.6.1 South America Influenza Vaccination Market Size & Forecasts, 2020-2031
9.6.2 By Country, South America Influenza Vaccination Market Size Market Share
9.7 Middle East & Africa

10 Sights by Country Level
10.1 By Country, Global Influenza Vaccination Market Size & CAGR，2020 VS 2024 VS 2031
10.2 By Country, Global Influenza Vaccination Market Size, 2020-2031
10.3 United States
10.3.1 United States Influenza Vaccination Market Size, 2020-2031
10.3.2 By Company, United States Influenza Vaccination Revenue Market Share, 2024
10.3.3 by Type, United States Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.3.4 by Application, United States Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.4 Europe
10.4.1 Europe Influenza Vaccination Market Size, 2020-2031
10.4.2 By Company, Europe Influenza Vaccination Revenue Market Share, 2024
10.4.3 by Type, Europe Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.4.4 by Application, Europe Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.5 China
10.5.1 China Influenza Vaccination Market Size, 2020-2031
10.5.2 By Company, China Influenza Vaccination Revenue Market Share, 2024
10.5.3 by Type, China Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.5.4 by Application, China Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.6 Japan
10.6.1 Japan Influenza Vaccination Market Size, 2020-2031
10.6.2 By Company, Japan Influenza Vaccination Revenue Market Share, 2024
10.6.3 by Type, Japan Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.6.4 by Application, Japan Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.7 South Korea
10.7.1 South Korea Influenza Vaccination Market Size, 2020-2031
10.7.2 By Company, South Korea Influenza Vaccination Revenue Market Share, 2024
10.7.3 by Type, South Korea Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.7.4 by Application, South Korea Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.8 Southeast Asia
10.8.1 Southeast Asia Influenza Vaccination Market Size, 2020-2031
10.8.2 By Company, Southeast Asia Influenza Vaccination Revenue Market Share, 2024
10.8.3 by Type, Southeast Asia Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.8.4 by Application, Southeast Asia Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.9 India
10.9.1 India Influenza Vaccination Market Size, 2020-2031
10.9.2 By Company, India Influenza Vaccination Revenue Market Share, 2024
10.9.3 by Type, India Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.9.4 by Application, India Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.10 Middle East & Africa
10.10.1 Middle East & Africa Influenza Vaccination Market Size, 2020-2031
10.10.2 By Company, Middle East & Africa Influenza Vaccination Revenue Market Share, 2024
10.10.3 by Type, Middle East & Africa Influenza Vaccination Revenue Market Share, 2024 VS 2031
10.10.4 by Application, Middle East & Africa Influenza Vaccination Revenue Market Share, 2024 VS 2031

11 Company Profile
11.1 Sanofi
11.1.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
11.1.2 Sanofi Company Profile and Main Business
11.1.3 Sanofi Influenza Vaccination Models, Specifications, and Application
11.1.4 Sanofi Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.1.5 Sanofi Recent Developments
11.2 CSL
11.2.1 CSL Company Information, Head Office, Market Area, and Industry Position
11.2.2 CSL Company Profile and Main Business
11.2.3 CSL Influenza Vaccination Models, Specifications, and Application
11.2.4 CSL Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.2.5 CSL Recent Developments
11.3 GSK
11.3.1 GSK Company Information, Head Office, Market Area, and Industry Position
11.3.2 GSK Company Profile and Main Business
11.3.3 GSK Influenza Vaccination Models, Specifications, and Application
11.3.4 GSK Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.3.5 GSK Recent Developments
11.4 Viatris
11.4.1 Viatris Company Information, Head Office, Market Area, and Industry Position
11.4.2 Viatris Company Profile and Main Business
11.4.3 Viatris Influenza Vaccination Models, Specifications, and Application
11.4.4 Viatris Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.4.5 Viatris Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
11.5.2 AstraZeneca Company Profile and Main Business
11.5.3 AstraZeneca Influenza Vaccination Models, Specifications, and Application
11.5.4 AstraZeneca Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.5.5 AstraZeneca Recent Developments
11.6 Hualan Bio
11.6.1 Hualan Bio Company Information, Head Office, Market Area, and Industry Position
11.6.2 Hualan Bio Company Profile and Main Business
11.6.3 Hualan Bio Influenza Vaccination Models, Specifications, and Application
11.6.4 Hualan Bio Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.6.5 Hualan Bio Recent Developments
11.7 Changchun Institute of Biological
11.7.1 Changchun Institute of Biological Company Information, Head Office, Market Area, and Industry Position
11.7.2 Changchun Institute of Biological Company Profile and Main Business
11.7.3 Changchun Institute of Biological Influenza Vaccination Models, Specifications, and Application
11.7.4 Changchun Institute of Biological Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.7.5 Changchun Institute of Biological Recent Developments
11.8 Sinovac
11.8.1 Sinovac Company Information, Head Office, Market Area, and Industry Position
11.8.2 Sinovac Company Profile and Main Business
11.8.3 Sinovac Influenza Vaccination Models, Specifications, and Application
11.8.4 Sinovac Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.8.5 Sinovac Recent Developments
11.9 BCHT
11.9.1 BCHT Company Information, Head Office, Market Area, and Industry Position
11.9.2 BCHT Company Profile and Main Business
11.9.3 BCHT Influenza Vaccination Models, Specifications, and Application
11.9.4 BCHT Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.9.5 BCHT Recent Developments
11.10 Jiangsu GDK
11.10.1 Jiangsu GDK Company Information, Head Office, Market Area, and Industry Position
11.10.2 Jiangsu GDK Company Profile and Main Business
11.10.3 Jiangsu GDK Influenza Vaccination Models, Specifications, and Application
11.10.4 Jiangsu GDK Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.10.5 Jiangsu GDK Recent Developments
11.11 KM Biologics
11.11.1 KM Biologics Company Information, Head Office, Market Area, and Industry Position
11.11.2 KM Biologics Company Profile and Main Business
11.11.3 KM Biologics Influenza Vaccination Models, Specifications, and Application
11.11.4 KM Biologics Influenza Vaccination Revenue and Gross Margin, 2020-2025
11.11.5 KM Biologics Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for Influenza Vaccination should grow from US$ 9713 million in 2024 to US$ 14080 million by 2031, with a CAGR of 5.2% for the period of 2025-2031.

Influenza vaccination is the public-health intervention of administering approved influenza vaccines to individuals—seasonally or by risk-based strategies—to establish immunity against circulating influenza strains, thereby reducing infection rates, severe disease, and healthcare burden. Vaccination is delivered across community, clinical, school, and corporate settings and can utilize inactivated, live-attenuated, recombinant-protein, or emerging mRNA/genetic platforms. Beyond reducing individual disease, influenza vaccination mitigates healthcare-system strain during seasonal peaks, preserves workforce and service continuity among key populations, and reduces broader economic impacts—delivering measurable public and commercial returns for governments, corporations, and insurers. Recent platform innovation, diversified delivery channels, and regulatory streamlining are shifting vaccination from a one-off public-health measure to a routine, value-bearing service.In 2024,   global Influenza vaccination production reached approximately 845.8 m units, with an average global market   price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%.

Influenza Vaccination

According to YH Research, the global market for Influenza Vaccination should grow from US$ 9713 million in 2024 to US$ 14080 million by 2031, with a CAGR of 5.2% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Influenza vaccination is in a transitional window from being a “seasonal public-health tool” to becoming a component of routine health management and organizational risk mitigation. Governments, insurers, and corporate risk managers increasingly prioritize vaccination to reduce healthcare system strain during seasonal peaks, creating durable policy and procurement support. Major vaccine manufacturers’ annual reports highlight platform upgrades— including recombinant and mRNA approaches—faster formulation updating, and measures to broaden access; these enhancements enable more responsive value chains that can better match circulating strains and support higher product and service value. Regulatory improvements aimed at preparedness and international collaboration are also enhancing institutional support for cross-border supply and R&D partnerships. For companies and investors, this is an opportunity to embed vaccination into corporate health programs, insurance product design, and long-term public procurement strategies.

Despite clear opportunities, the industry faces systemic risks: viral antigenic drift and the uncertainty of strain-vaccine matching demand high flexibility in R&D and manufacturing release cycles; vaccination uptake remains sensitive to public awareness, payment mechanisms, and access, causing demand variability in some regions; dependence on specific upstream materials and production assets means that regional policy or logistics disruptions can impact capacity; and the rapid market entry of new technology platforms alters competitive dynamics, forcing incumbents to sustain investment in capital and production upgrades. Annual reports frequently warn of market volatility, regulatory heterogeneity, and the complexity of managing diverse distribution channels—factors that require measured expansion strategies.

Demand is shifting from purely seasonal vaccination toward structured, routine immunization programs focused on high-risk groups and institutional delivery. Hospitals, long-term care facilities, schools, and large employers increasingly incorporate influenza vaccination into annual health plans or employee benefits, favoring centralized procurement and mass-vaccination approaches. The expansion of community vaccination sites, pharmacy-based services, mobile clinics, and digital scheduling systems is improving accessibility and uptake. Consumer preference for higher-efficacy products and lower reactogenicity is accelerating penetration of quadrivalent, high-dose, or adjuvanted vaccines. Corporate annual reports and government communications alike indicate that service convenience, scenario-based delivery, and product differentiation are the three principal factors driving downstream willingness to pay.

Upstream inputs include seed viruses or expression vectors, cell substrates or egg-based matrices and specialized culture systems, adjuvant formulations, and sterile-filling consumables—forming a supply landscape characterized by high technical requirements and relative concentration. Annual reports show that advanced platforms demand greater purity, consistency, and traceability from raw materials, raising the technical threshold for supply-chain management and making upstream suppliers strategic partners. As multiple production platforms coexist, upstream differentiation will directly influence process efficiency, capacity scalability, and cost structure. Cold-chain packaging and quality-control reagents are also critical upstream elements, and their reliability and compliance are essential for cross-border supply and large-scale campaigns. Companies commonly emphasize strategic procurement, supplier diversification, and long-term contracts to mitigate upstream risk.

This report aims to provide a comprehensive study of the global market for Influenza Vaccination. Report Highlights:
(1) Global Influenza Vaccination market size (value), history data from 2020-2024, and forecast data from 2025 to 2031.

(2) Global Influenza Vaccination market competitive situation, revenue, and market share, from 2020 to 2024.

(3) China Influenza Vaccination market competitive situation, revenue, and market share, from 2020 to 2024.

(4) Global Influenza Vaccination segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Influenza Vaccination segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Influenza Vaccination industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
    Trivalent Influenza Vaccine
    Quadrivalent Influenza Vaccine

Market segment by Technology, covers
    Chicken Embryo Technology
    Cell Culture Technology
    Recombinant Technology
    Adjuvant Vaccines

Market segment by Administration, covers
    Injectable
    Nasal Spray

Market segment by Application, can be divided into
    6 Months to 3 Years
    > 3 Years

Market segment by players, this report covers
    Sanofi
    CSL
    GSK
    Viatris
    AstraZeneca
    Hualan Bio
    Changchun Institute of Biological
    Sinovac
    BCHT
    Jiangsu GDK
    KM Biologics